论文部分内容阅读
目的 了解过继免疫治疗（ＡＩＴ） 疗程中ＮＫ活性变化与骨转移瘤患病机体免疫状况与致命再转移的关系。方法 对２０ 例骨转移瘤转输自体ＬＡＫ、ＴＩＬ前后作了ＮＫ 活性动态性监测，所测参数与１０ 例正常人作了分析比较。结果 正常对照组平均ＮＫ活性率（４９ ．５±１２．２）％ ；ＬＡＫ组治疗前平均ＮＫ活性（１９．９±２０．５） ％ ，治疗后平均活性（３５ ．４８ ±１７．４４）％ ，与正常对照组比较差异有显著性（ Ｐ＜ ０．０５）；ＴＩＬ组治疗前平均活性（５．８０ ±９．９０）％ ，治疗后平均活性（７８．２１±４９．９１） ％ ，与正常对照组比较差异有显著性（Ｐ＜ ０．０１） ；ＬＡＫ 组与ＴＩＬ组比较差异有显著性（Ｐ＜ ０．０１）。结论 动态个体ＮＫ活性监测用以判断机体免疫状态与疗效较为客观，可作为监测恶瘤再转移的参考指标。
Objective To investigate the relationship between the change of NK activity and the fatal retransmission of bone metastases in the course of adoptive immunotherapy (AIT). Methods The dynamic changes of NK activity were measured before and after transfusion of autologous LAK and TIL in 20 patients with bone metastases. The measured parameters were compared with 10 normal controls. Results The average NK activity rate of the normal control group was (49. 5±12.2)%; the average NK activity before treatment in the LAK group was (19.9±20.5)%, and the average activity after treatment was (35.48±17.44) %, compared with the normal control group, the difference was significant (P<0.05); the average activity before treatment (5.80±9.90)% in the TIL group, and the average activity after the treatment (78.21±49.91) % There was a significant difference between the control group and the normal control group (P<0.01), and there was a significant difference between the LAK group and the TIL group (P<0.01). Conclusion The dynamic individual NK activity monitoring can be used to judge the immune status and efficacy of the body. It can be used as a reference index to monitor the recurrence of malignant tumors.